Sign In
Buy EVR
$340.09
-6.97 (-2.01%)
At Close: Jun 03, 2026
Evercore Stock Soars Nearly 38% in 6 Months: Is There More Room to Run?
03:11pm, Monday, 01'st Dec 2025
After EVR's 37.9% six-month surge, can its strong investment banking momentum and solid liquidity keep powering the stock higher? Let us discuss.
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
09:00am, Monday, 01'st Dec 2025
Management to Participate in 8th Annual Evercore Annual Healthcare Conference Management to Participate in 8th Annual Evercore Annual Healthcare Conference
Charles River Laboratories to Present at Evercore Healthcare Conference
08:00am, Monday, 01'st Dec 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Evercore Healthcare Conference.
ProQR to Participate in 8th Annual Evercore Healthcare Conference
08:00am, Monday, 01'st Dec 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
07:00am, Monday, 01'st Dec 2025
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
07:00am, Monday, 01'st Dec 2025
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat ro
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
07:00am, Monday, 01'st Dec 2025
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
Why Is Evercore (EVR) Up 8.8% Since Last Earnings Report?
12:31pm, Friday, 28'th Nov 2025
Evercore (EVR) reported earnings 30 days ago. What's next for the stock?
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
07:30am, Friday, 28'th Nov 2025
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th
Evercore ISI's Mark Mahaney on Alphabet: ‘The fundamentals look great'
10:57am, Wednesday, 26'th Nov 2025
Mark Mahaney, head of internet research at Evercore ISI, joins CNBC's ‘Squawk on the Street' to discuss Alphabet as the tech giant's stock surges to all-time highs, the ongoing AI race, and more.
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
08:00am, Wednesday, 26'th Nov 2025
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conferen
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
06:45am, Wednesday, 26'th Nov 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference.
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
08:30am, Tuesday, 25'th Nov 2025
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host i
Evercore Hosts 8th Annual Healthcare Conference, Dec. 2-4, 2025
08:00am, Tuesday, 25'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Evercore (NYSE: EVR) will host its 8th annual Healthcare Conference at the Loews Coral Gables Hotel in Coral Gables, Florida, Dec. 2-4, 2025. This year's conference features
Septerna to Participate in 8th Annual Evercore Healthcare Conference
08:00am, Tuesday, 25'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc
